Skip to main content
Top
Published in: European Spine Journal 4/2019

01-04-2019 | Thrombosis | Expert's Comment

Expert’s comment concerning Grand Rounds case entitled “Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation” by Deekonda P, Stokes OM, Chan D (Eur Spine J [2016]: DOI 10.1007/s00586-016-4822-8)

Author: Anthony Todd

Published in: European Spine Journal | Issue 4/2019

Login to get access

Excerpt

This is a clear and well-constructed case report describing retroperitoneal haemorrhage in a 72-year-old man taking the oral anticoagulant, rivaroxaban, shortly after spinal surgery and a related literature review [1]. The authors describe the patient’s presentation and bleeding management as well as summarise some key issues around NOACs and surgery. …
Literature
4.
go back to reference Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M (2013) Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 160(1):35–46CrossRefPubMed Makris M, Van Veen JJ, Tait CR, Mumford AD, Laffan M (2013) Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol 160(1):35–46CrossRefPubMed
5.
go back to reference Clinical Excellence Commission (2017) Non-vitamin K antagonist oral anticoagulant (NOAC) Guidelines, Updated July 2017. Sydney, Australia Clinical Excellence Commission (2017) Non-vitamin K antagonist oral anticoagulant (NOAC) Guidelines, Updated July 2017. Sydney, Australia
6.
go back to reference Sarode R, Milling TJ Jr, Refaai MA et al (2013) Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 128:1234–1243CrossRefPubMedPubMedCentral Sarode R, Milling TJ Jr, Refaai MA et al (2013) Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 128:1234–1243CrossRefPubMedPubMedCentral
7.
go back to reference Levy JH, Moore KT, Neal MD, Schneider D, Marcsisin VS, Ariyawansa J, Weitz JJ (2018) Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. Thromb Haemost 16(1):54–64CrossRef Levy JH, Moore KT, Neal MD, Schneider D, Marcsisin VS, Ariyawansa J, Weitz JJ (2018) Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. Thromb Haemost 16(1):54–64CrossRef
8.
go back to reference Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R (2011) Clinical review: prothrombin complex concentrates—evaluation of safety and thrombogenicity. Crit Care 15(1):201–209CrossRefPubMedPubMedCentral Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R (2011) Clinical review: prothrombin complex concentrates—evaluation of safety and thrombogenicity. Crit Care 15(1):201–209CrossRefPubMedPubMedCentral
15.
go back to reference Hylek EM, Held C, Alexander JH et al (2014) Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 63(20):2148–2150. https://doi.org/10.1016/j.jacc.2014.02.549 CrossRef Hylek EM, Held C, Alexander JH et al (2014) Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 63(20):2148–2150. https://​doi.​org/​10.​1016/​j.​jacc.​2014.​02.​549 CrossRef
18.
go back to reference Sherwood MW, Douketis JD, Patel MR et al (2014) Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation 129(18):1850–1859CrossRefPubMedPubMedCentral Sherwood MW, Douketis JD, Patel MR et al (2014) Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation 129(18):1850–1859CrossRefPubMedPubMedCentral
Metadata
Title
Expert’s comment concerning Grand Rounds case entitled “Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation” by Deekonda P, Stokes OM, Chan D (Eur Spine J [2016]: DOI 10.1007/s00586-016-4822-8)
Author
Anthony Todd
Publication date
01-04-2019
Publisher
Springer Berlin Heidelberg
Published in
European Spine Journal / Issue 4/2019
Print ISSN: 0940-6719
Electronic ISSN: 1432-0932
DOI
https://doi.org/10.1007/s00586-018-5843-2

Other articles of this Issue 4/2019

European Spine Journal 4/2019 Go to the issue

Announcements

Announcements